Iovance Biotherapeutics Inc IOVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IOVA is a good fit for your portfolio.
News
-
Thinking about buying stock in SoundHound AI, Intuitive Machines, Iovance Biotherapeutics, Silence Therapeutics, or Altimmune?
-
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145
-
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
-
Thinking about buying stock in Synchronoss, ZIM Integrated Shipping, Iovance Biotherapeutics, Sirius XM, or Lincoln Educational Services?
-
Thinking about buying stock in C4 Therapeutics, Safety Shot, Intuitive Machines, Cardiol Therapeutics, or Iovance Biotherapeutics?
-
Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals
-
Thinking about buying stock in Iovance Biotherapeutics, Alaska Energy Metals, Foremost Lithium Resource & Technology, Shineco, or Intuitive Machines?
-
Iovance Says Amtagvi Gets Accelerated Approval for Advanced Melanoma
Trading Information
- Previous Close Price
- $11.32
- Day Range
- $11.41–11.97
- 52-Week Range
- $3.21–18.33
- Bid/Ask
- $11.61 / $12.98
- Market Cap
- $3.31 Bil
- Volume/Avg
- 1 / 9.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,317.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 557
- Website
- https://www.iovance.com
Comparables
Valuation
|
Metric
|
IOVA
|
NUVL
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.13 | 5.90 | 10.50 |
Price/Sales | 2,317.58 | — | 10.11 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IOVA
|
NUVL
|
MRSN
|
|---|---|---|---|
Quick Ratio | 2.54 | 22.62 | 3.29 |
Current Ratio | 2.79 | 22.83 | 3.36 |
Interest Coverage | — | — | −44.11 |
Quick Ratio
IOVA
NUVL
MRSN
Profitability
|
Metric
|
IOVA
|
NUVL
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −49.22% | −19.79% | −49.57% |
Return on Equity (Normalized) | −63.56% | −20.76% | −211.52% |
Return on Invested Capital (Normalized) | −57.91% | −25.56% | −146.81% |
Return on Assets
IOVA
NUVL
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Flsqqrmvl | Tztq | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bpczhxmkp | Xncyzg | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Csnztbpj | Wygdlw | $99.6 Bil | |
MRNA
| Moderna Inc | Sqkbbnpm | Grcpx | $38.8 Bil | |
ARGX
| argenx SE ADR | Gmcrdrdx | Rznc | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Mnsdmpm | Qth | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Spthbnnx | Ysdnrd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Txlggfcd | Ywdhc | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yqnmyrlyzs | Mwmjw | $12.4 Bil | |
INCY
| Incyte Corp | Rjgsfzyl | Msrkt | $11.9 Bil |